Insulin Management for Gestational and Type 2 Diabetes in Pregnancy
- PMID: 38870526
- DOI: 10.1097/AOG.0000000000005640
Insulin Management for Gestational and Type 2 Diabetes in Pregnancy
Abstract
Insulin is preferred as the first-line agent for glucose management of gestational diabetes mellitus and type 2 diabetes in pregnancy when nutritional and lifestyle modifications are unable to achieve pregnancy-specific glucose targets. Individual heterogeneity in defects of insulin secretion or sensitivity in liver and muscle, unique genetic influences on pregnancy glycemic regulation, and variable cultural and lifestyle behaviors that affect meal, activity, sleep, and occupational schedules necessitate a personalized approach to insulin regimens. Newer insulin preparations have been developed to mimic the physiologic release of endogenous insulin, maintaining appropriate basal levels to cover hepatic gluconeogenesis and simulate the rapid, meal-related, bolus rise of insulin. Such physiologic basal-bolus dosing of insulin can be administered safely, achieving tighter glycemic control while reducing episodes of hypoglycemia. Insulin initiation and titration require understanding the pharmacodynamics of different insulin preparations in addition to a patient's glycemic profiles, effect of variable nutritional intake and mealtimes, physical activity, stress, timing of sleep cycles, and cultural habits. Educating and empowering patients to learn how their glucose responds to insulin, portion and content of meals, and physical activity can increase personal engagement in therapy, flexibility in eating patterns, and improved glycemic control. This Clinical Expert Series article is focused on optimizing insulin management (initiation, dosing, and titration) of gestational and type 2 diabetes in pregnancy.
Copyright © 2024 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Financial Disclosure The authors did not report any potential conflicts of interest.
References
-
- Centers for Disease Control and Prevention. QuickStats: Percentage of Mothers with Gestational Diabetes, by Maternal Age—National Vital Statistics System, United States, 2016 and 2021. Accessed February 24, 2024. https://blogs.cdc.gov/nchs/2023/01/06/7230/
-
- Pregestational diabetes mellitus. ACOG Practice Bulletin No. 201. American College of Obstetricians and Gynecologists. Obstet Gynecol 2018;132:e228–48. doi: 10.1097/aog.0000000000002960 - DOI
-
- American Diabetes Association Professional Practice Committee. 15. Management of diabetes in pregnancy: standards of care in diabetes—2024. Diabetes Care 2024;47(suppl 1):S282–94. doi: 10.2337/dc24-S015 - DOI
-
- American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes-2024. Diabetes Care 2024;47(suppl 1):S158–78. doi: 10.2337/dc24-S009 - DOI
-
- Feig DS, Donovan LE, Zinman B, Sanchez JJ, Asztalos E, Ryan EA, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2020;8:834–44. doi: 10.1016/s2213-8587(20)30310-7 - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical